This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2.1%. By the end of trading, Teva Pharmaceutical Industries rose 64 cents (1.6%) to $40.07 on average volume. Throughout the day, 3.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.9 million shares. The stock ranged in a price between $39.40-$40.10 after having opened the day at $39.44 as compared to the previous trading day's close of $39.43. Other companies within the Drugs industry that increased today were: AVI BioPharma ( AVII), up 530.5%, Peregrine Pharmaceuticals ( PPHM), up 23%, Catalyst Pharmaceutical Partners ( CPRX), up 21.9%, and Affymax ( AFFY), up 19.2%.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.22 billion and is part of the health care sector. The company has a P/E ratio of 12.7, above the average drugs industry P/E ratio of 12.2 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.7% year to date as of the close of trading on Wednesday. Currently there are 20 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself.

On the negative front, Ampio Pharmaceuticals ( AMPE), down 14.5%, Complete Genomics ( GNOM), down 13%, Prima Biomed Ltd. ADR ( PBMD), down 10.3%, and MEI Pharma ( MEIP), down 10%, were all losers within the drugs industry with AstraZeneca ( AZN) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 16,864.94 -177.96 -1.04%
S&P 500 1,956.24 -16.05 -0.81%
NASDAQ 4,442.8650 -50.5250 -1.12%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs